Physician profile
Daniel Paul Singer
NPI 1629048905
$305,658.41
in general payments reported to CMS, 2019-2025
45 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $35K · 2021: $68K · 2022: $61K · 2023: $27K · 2024: $19K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $4,165 · Consulting Fee: $2,638 · Travel and Lodging: $522 · Education: $15.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,755.50 |
| Food and Beverage | $4,165.14 |
| Consulting Fee | $2,638.00 |
| Travel and Lodging | $522.08 |
| Education | $15.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $105,699.29 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $84,688.25 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $69,143.54 | 2019-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $16,843.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14,381.78 | 2022 | |
| Allergan, INC. | $8,249.39 | 2019-2021 | |
| Pfizer INC. | $2,504.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $350.40 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $347.12 | 2023-2024 | Aptiom |
| Csl Behring | $325.49 | 2019-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $315.27 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Ucb, INC. | $313.95 | 2019-2024 | Briviact, Rystiggo, Nayzilam |
| Genentech USA, INC. | $244.99 | 2019-2024 | Ocrevus, Enspryng |
| Genzyme Corporation | $236.69 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $223.96 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.